发布求助
文献互助 智能选刊 最新文献

Current Opinion in Pharmacology最新文献

筛选
英文 中文
Allogeneic double-negative T-cell therapy for acute myeloid leukemia 异基因双阴性t细胞治疗急性髓性白血病
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2025-05-10 DOI: 10.1016/j.coph.2025.102537
Enoch Tin , Jongbok Lee , Li Zhang
{"title":"Allogeneic double-negative T-cell therapy for acute myeloid leukemia","authors":"Enoch Tin ,&nbsp;Jongbok Lee ,&nbsp;Li Zhang","doi":"10.1016/j.coph.2025.102537","DOIUrl":"10.1016/j.coph.2025.102537","url":null,"abstract":"<div><div>CD3<sup>+</sup>CD4<sup>−</sup>CD8<sup>−</sup> double-negative T cells (DNTs) represent a unique subset of T lymphocytes with potent cytotoxicity against acute myeloid leukemia (AML). Importantly, allogeneic DNTs do not induce graft-versus-host disease and have demonstrated characteristics suitable for off-the-shelf cellular therapy with promising efficacy in early-stage clinical trials. DNT therapy can synergize with conventional AML treatments and can be transduced with chimeric antigen receptors (CARs). Notably, persistent CAR<sup>+</sup> T cells in patients, who achieved long-term remission, predominantly have a DNT phenotype. The unique and versatile therapeutic properties of allogeneic DNTs position them as a strong candidate among adoptive cellular therapies for AML.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"83 ","pages":"Article 102537"},"PeriodicalIF":4.0,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144155159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Colloidal drug delivery systems for infectious diseases of skin 皮肤传染病用胶体给药系统
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2025-05-10 DOI: 10.1016/j.coph.2025.102536
Sopan Nangare , Varda Joshi , Shrikant Magdum , Riya Patil , Vishin Patil
{"title":"Colloidal drug delivery systems for infectious diseases of skin","authors":"Sopan Nangare ,&nbsp;Varda Joshi ,&nbsp;Shrikant Magdum ,&nbsp;Riya Patil ,&nbsp;Vishin Patil","doi":"10.1016/j.coph.2025.102536","DOIUrl":"10.1016/j.coph.2025.102536","url":null,"abstract":"<div><div>Infectious skin diseases represent a major global health burden, demanding effective and affordable treatments. Conventional therapies often face challenges such as reduced bioavailability, enzymatic degradation, low permeability, and poor solubility. Colloidal-based transdermal drug delivery systems, including liposomes, ethosomes, niosomes, nanoemulsions, polymeric nanoparticles, micelles, solid lipid nanoparticles, etc., have emerged as promising alternatives. In brief, these colloidal systems enhance drug penetration, stability, biocompatibility, and customized release while improving antimicrobial efficacy against various pathogens and minimizing systemic side effects. In conclusion, colloidal formulations offer a targeted, efficient approach, optimizing therapeutic outcomes, improving patient compliance, and advancing the treatment of infectious skin diseases.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"83 ","pages":"Article 102536"},"PeriodicalIF":4.0,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144168264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fitness in acute myeloid leukemia, state of the art and future directions 急性髓性白血病的适应性，现状和未来方向
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2025-04-26 DOI: 10.1016/j.coph.2025.102527
Raffaele Palmieri , Luca Maurillo , Maria Ilaria Del Principe , Adriano Venditti , Francesco Buccisano
{"title":"Fitness in acute myeloid leukemia, state of the art and future directions","authors":"Raffaele Palmieri ,&nbsp;Luca Maurillo ,&nbsp;Maria Ilaria Del Principe ,&nbsp;Adriano Venditti ,&nbsp;Francesco Buccisano","doi":"10.1016/j.coph.2025.102527","DOIUrl":"10.1016/j.coph.2025.102527","url":null,"abstract":"<div><div>Acute Myeloid Leukemia (AML) is a complex disease whose outcome can be variably influenced by several clinical and biological factors. Although there is still no consensus on how to integrate these elements to best guide treatment choice, multiparametric models, commonly called fitness scores, have been developed to evaluate each patient's ability to tolerate therapies. These models consider various risk factors, including disease biology, comorbidities, physical and cognitive function. To date, several scoring systems can be used to categorize patients on their fitness for intensive or non-intensive therapies. However, existing tools mainly focus on identifying patients suitable for conventional intensive chemotherapy and fail to address the complexities of less-fit patients who might benefit from innovative intensive, less-intensive, and even maintenance strategies. As treatment landscapes are in constant evolution, identifying intermediate level of fitness through recalibration of existing scores or development of new ones should be prioritized. Considering all the above, this review aims to report on the state of the art of fitness assessment in AML and discuss possible future directions on this topic.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"83 ","pages":"Article 102527"},"PeriodicalIF":4.0,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143947657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic hurdles in acute myeloid leukemia: Leukemic stem cells, inflammation and immune dysfunction 急性髓系白血病的治疗障碍：白血病干细胞、炎症和免疫功能障碍
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2025-04-08 DOI: 10.1016/j.coph.2025.102526
Bofei Wang , Patrick K. Reville , Hussein A. Abbas
{"title":"Therapeutic hurdles in acute myeloid leukemia: Leukemic stem cells, inflammation and immune dysfunction","authors":"Bofei Wang ,&nbsp;Patrick K. Reville ,&nbsp;Hussein A. Abbas","doi":"10.1016/j.coph.2025.102526","DOIUrl":"10.1016/j.coph.2025.102526","url":null,"abstract":"<div><div>Acute myeloid leukemia (AML) is an aggressive and highly heterogeneous hematological malignancy characterized by clonal expansion and differentiation arrest in myeloid progenitor cells. Despite advancements in chemotherapy, allogeneic hematopoietic stem cell transplantation, and post-remission maintenance therapies, the long-term survival remains unsatisfactory with high rates of relapse and refractory. These therapeutic challenges are mediated by multiple factors, including the complexity of the cellular hierarchies in AML, the interaction of leukemic stem cells (LSCs) with the bone marrow niche, inflammation, and immune evasion mechanisms. Further, the absence of specific surface markers that distinguish LSCs from normal hematopoietic stem cells, together with LSCs’ functional heterogeneity, complicates targeted treatment approaches. Immune dysfunction, including T cell exhaustion and immune suppression within the bone marrow niche contributes to therapy resistance. In this brief review, we aim to explore current challenges in AML therapy, focusing on LSC-driven resistance, immune evasion, and the need for innovative therapeutic strategies.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"82 ","pages":"Article 102526"},"PeriodicalIF":4.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143899387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel approaches to CAR T cell target identification in acute myeloid leukemia 急性髓性白血病CAR - T细胞靶标鉴定的新方法
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2025-04-08 DOI: 10.1016/j.coph.2025.102524
Gordon Victor Hoffmann , Adrian Gottschlich , Marion Subklewe , Sebastian Kobold
{"title":"Novel approaches to CAR T cell target identification in acute myeloid leukemia","authors":"Gordon Victor Hoffmann ,&nbsp;Adrian Gottschlich ,&nbsp;Marion Subklewe ,&nbsp;Sebastian Kobold","doi":"10.1016/j.coph.2025.102524","DOIUrl":"10.1016/j.coph.2025.102524","url":null,"abstract":"<div><div>Identifying safe and effective CAR T cell targets in acute myeloid leukemia (AML) is challenging due to the disease’s complexity and overlap with normal hematopoiesis. This review highlights advances in target discovery for AML, emphasizing innovative approaches. Structural surfaceomics identifies tumor-specific protein conformations, while AI-driven single-cell RNA sequencing integrates multi-source data to pinpoint optimal targets. Refined cell surface capture technology maps the AML surfaceome without relying on predefined antibodies. These strategies enhance CAR T cell specificity and minimize off-tumor effects, offering promising pathways for safer and more effective AML treatments and broader cancer therapies.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"82 ","pages":"Article 102524"},"PeriodicalIF":4.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143892136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Strategies to enhance anti-leukaemia immunotherapy 加强抗白血病免疫治疗的策略
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2025-04-04 DOI: 10.1016/j.coph.2025.102525
Memnon Lysandrou, Robert Zeiser
{"title":"Strategies to enhance anti-leukaemia immunotherapy","authors":"Memnon Lysandrou,&nbsp;Robert Zeiser","doi":"10.1016/j.coph.2025.102525","DOIUrl":"10.1016/j.coph.2025.102525","url":null,"abstract":"<div><div>Acute myeloid leukaemia (AML) was an incurable disease prior to allogeneic haematopoietic cell transplantation (allo-HCT), which was proven to be a potent cellular immunotherapy-approach. However, allo-HCT has major side effects, with disease relapse presenting as a frequent complication. Novel immunotherapies aim to reduce toxicity and increase the anti-leukaemia activity of allo-HCT. Technological advancements in genetic engineering approaches enable potent immunotherapeutic activity while limiting toxicities. A biology-driven application of small molecules that target AML vulnerabilities holds promise to enhance anti-leukaemia immunotherapy. Extensive preclinical testing of these approaches is essential to reduce toxicity and to find the ideal combination partners for future clinical testing.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"82 ","pages":"Article 102525"},"PeriodicalIF":4.0,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143860016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lipids and lipid regulators in intraocular pressure homeostasis 眼内压稳态中的脂质和脂质调节因子
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2025-03-21 DOI: 10.1016/j.coph.2025.102523
Gregory T. Rognon , Anna Yu-an Liao , Rodahina Philihina Pasteurin , Avinash Soundararajan , Padmanabhan Paranji Pattabiraman
{"title":"Lipids and lipid regulators in intraocular pressure homeostasis","authors":"Gregory T. Rognon ,&nbsp;Anna Yu-an Liao ,&nbsp;Rodahina Philihina Pasteurin ,&nbsp;Avinash Soundararajan ,&nbsp;Padmanabhan Paranji Pattabiraman","doi":"10.1016/j.coph.2025.102523","DOIUrl":"10.1016/j.coph.2025.102523","url":null,"abstract":"<div><div>Increased intraocular pressure is the strongest correlated modifiable risk factor for developing primary open-angle glaucoma (POAG). Lipids have long been known to be a major constituent of aqueous humor. Lipid mediators, prostaglandins for example, are the first-line treatment for glaucoma. Innovative technologies have made the investigation of lipids in small quantities possible, and interest in identifying lipids as new pharmacological targets has grown in ophthalmology. There is expanding evidence to suggest that lipids and their active metabolites play a role in POAG pathophysiology, as differences between control and diseased eyes have now been demonstrated. The role of these differences is yet to be determined and is the subject of this review.</div></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"82 ","pages":"Article 102523"},"PeriodicalIF":4.0,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143834899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Balancing genome integrity and carcinogenesis: Insights into DNA damage response, repair pathways, and cancer therapies 平衡基因组完整性和癌变：洞察DNA损伤反应，修复途径和癌症治疗
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2025-03-19 DOI: 10.1016/j.coph.2025.102522
Sudha Sharma, Srijita Dhar, Sagar Sengupta
{"title":"Balancing genome integrity and carcinogenesis: Insights into DNA damage response, repair pathways, and cancer therapies","authors":"Sudha Sharma,&nbsp;Srijita Dhar,&nbsp;Sagar Sengupta","doi":"10.1016/j.coph.2025.102522","DOIUrl":"10.1016/j.coph.2025.102522","url":null,"abstract":"","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"82 ","pages":"Article 102522"},"PeriodicalIF":4.0,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143792818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Message from the New Editor-in-Chief, Prof. Sheng-Tao Hou 新任总编辑侯胜涛教授寄语。
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2025-02-01 DOI: 10.1016/j.coph.2024.102504
Sheng-Tao Hou
{"title":"Message from the New Editor-in-Chief, Prof. Sheng-Tao Hou","authors":"Sheng-Tao Hou","doi":"10.1016/j.coph.2024.102504","DOIUrl":"10.1016/j.coph.2024.102504","url":null,"abstract":"","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"80 ","pages":"Article 102504"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143025552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In memoriam - Francesco di Virgilio: P2X7 receptors in purinergic pathophysiology 纪念- Francesco di Virgilio：嘌呤能病理生理中的P2X7受体。
IF 4 3区 医学
Current Opinion in Pharmacology Pub Date : 2025-02-01 DOI: 10.1016/j.coph.2024.102503
P. Illes , A. Verkhratsky , Y. Tang , P. Rubini , E. Adinolfi
{"title":"In memoriam - Francesco di Virgilio: P2X7 receptors in purinergic pathophysiology","authors":"P. Illes ,&nbsp;A. Verkhratsky ,&nbsp;Y. Tang ,&nbsp;P. Rubini ,&nbsp;E. Adinolfi","doi":"10.1016/j.coph.2024.102503","DOIUrl":"10.1016/j.coph.2024.102503","url":null,"abstract":"","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":"80 ","pages":"Article 102503"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143043271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信